stockrow
Saturday 7 November 2026
Export PHAT’s income statement to Excel — free account
Phathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024.
- Revenue
- +71.1%
- EPS
- +60.1%
- Free cash flow
- +112.2%
- Total debt
- −20.1%
Quarter to September 2026, against a year earlier
5.23
0.15
+2.95%
Follow PHAT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.25 | 3.79 | 4.45 | 6.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
336.99 | (470.81) | (58.26) | (241.90) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.22 | 3.76 | 4.42 | 7.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(29.46) | (24.56) | (9.28) | (7.79) | |
EV/FCF |
(29.04) | (24.41) | (9.25) | (7.78) | |
Quick Ratio |
1.67 | 1.82 | 2.09 | 1.58 | |
Current Ratio |
1.76 | 1.92 | 2.21 | 1.73 | |
Net Debt/EBITDA |
(19.25) | 6.09 | 1.19 | (15.85) | |
Debt/Assets |
47.98% | 50.32% | 53.64% | 80.68% | |
Debt/Equity |
(0.48) | (0.48) | (0.49) | (0.48) | |
Asset Turnover |
0.94 | 0.83 | 0.68 | 0.55 | |
Operating CF/Net income |
(0.13) | 0.11 | 0.52 | 0.24 | |
Capex/Depreciation |
(0.10) | (0.04) | (0.06) | (0.09) | |
Interest Coverage |
(0.01) | (0.26) | (0.98) | (0.36) | |
Research and Development Expense of Revenue |
10.32% | 10.52% | 13.33% | 13.01% | |
Selling, General and Administrative Expense of Revenue |
68.10% | 74.49% | 92.64% | 84.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.99% | 9.04% | 9.49% | 9.74% | |
Graham Net Nets |
(0.62) | (0.41) | (0.40) | (0.39) | |
Graham Number |
9.76 | 10.88 | 14.00 | 20.34 | |
Earnings Yield |
(14.16%) | (11.80%) | (19.08%) | (18.44%) | |
Free Cash Flow Yield |
(3.40%) | (4.06%) | (10.72%) | (13.81%) | |
Revenue per Share |
1.00 | 0.89 | 0.71 | 0.79 | |
Operating CF per Share |
0.02 | (0.02) | (0.19) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | (0.02) | (0.19) | (0.07) | |
Cash per Share |
2.17 | 2.18 | 2.20 | 1.78 | |
Shareholders Equity per Share |
(4.09) | (4.11) | (4.11) | (6.01) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.09) | (4.11) | (4.11) | (6.01) | |
Free Cash Flow |
1.73 | (1.97) | (15.71) | (5.09) | |
Working Capital |
133.11 | 142.14 | 151.53 | 96.93 | |
Capital Expenditures |
(0.11) | (0.04) | (0.06) | (0.09) | |
Net Current Asset Value |
(384.64) | (375.43) | (365.50) | (468.35) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
81.70 | 74.34 | 58.54 | 58.46 | |
Average Payables |
6.09 | 4.68 | 8.99 | 7.75 | |
Average Inventory |
5.62 | 5.57 | 4.84 | 4.36 | |
Average Assets |
292.65 | 288.65 | 299.66 | 318.73 | |
Average Common Equity |
(385.09) | (375.05) | (337.67) | (345.87) |
Columns are period end dates · fundamentals updated 2 Nov 2026